TVTX
Income statement / Annual
Last year (2023), Travere Therapeutics, Inc.'s total revenue was $145.24 M,
a decrease of 31.50% from the previous year.
In 2023, Travere Therapeutics, Inc.'s net income was -$111.40 M.
See Travere Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$145.24 M
|
$212.02 M
|
$227.49 M
|
$198.32 M
|
$175.34 M
|
$164.25 M
|
$154.94 M
|
$133.59 M
|
$99.89 M
|
$28.20 M
|
| Cost of Revenue |
$56.38 M |
$7.59 M |
$6.78 M |
$6.13 M |
$5.23 M |
$5.53 M |
$3.61 M |
$4.55 M |
$2.19 M |
$570,979.00 |
| Gross Profit |
$88.86 M |
$204.43 M |
$220.71 M |
$192.20 M |
$170.10 M |
$158.72 M |
$151.33 M |
$129.04 M |
$97.71 M |
$27.63 M |
| Gross Profit Ratio |
0.61 |
0.96 |
0.97 |
0.97 |
0.97 |
0.97 |
0.98 |
0.97 |
0.98 |
0.98 |
| Research and Development
Expenses |
$237.73 M
|
$235.78 M
|
$210.33 M
|
$131.77 M
|
$140.96 M
|
$123.76 M
|
$78.17 M
|
$70.85 M
|
$50.43 M
|
$47.80 M
|
| General & Administrative
Expenses |
$265.54 M
|
$220.21 M
|
$149.88 M
|
$135.80 M
|
$128.95 M
|
$103.65 M
|
$103.96 M
|
$98.02 M
|
$79.54 M
|
$59.64 M
|
| Selling & Marketing
Expenses |
-$37.67 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$227.87 M
|
$220.21 M
|
$149.88 M
|
$135.80 M
|
$128.95 M
|
$103.65 M
|
$103.96 M
|
$98.02 M
|
$79.54 M
|
$59.64 M
|
| Other Expenses |
$1.59 M |
$974,000.00 |
$231,000.00 |
$1.42 M |
-$314,000.00 |
-$474,000.00 |
$1.11 M |
-$264,000.00 |
-$296,000.00 |
$570.98 M |
| Operating Expenses |
$465.60 M |
$455.99 M |
$360.21 M |
$267.57 M |
$269.91 M |
$227.41 M |
$182.13 M |
$168.87 M |
$129.97 M |
$107.44 M |
| Cost And Expenses |
$521.98 M |
$463.58 M |
$367.00 M |
$273.70 M |
$275.15 M |
$232.94 M |
$185.73 M |
$173.42 M |
$132.15 M |
$108.01 M |
| Interest Income |
$21.77 M |
$6.28 M |
$1.99 M |
$5.00 M |
$10.06 M |
$5.50 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$11.33 M |
$11.28 M |
$20.14 M |
$19.05 M |
$18.83 M |
$9.81 M |
$1.19 M |
$34.48 M |
$7.75 M |
$55.02 M |
| Depreciation &
Amortization |
$38.53 M
|
$20.72 M
|
$26.62 M
|
$25.79 M
|
$20.41 M
|
$18.67 M
|
$17.80 M
|
$16.14 M
|
$13.39 M
|
$5.40 M
|
| EBITDA |
-$331.81 M
|
-$244.31 M
|
-$137.28 M
|
-$68.95 M
|
-$69.66 M
|
-$63.67 M
|
-$29.69 M
|
-$6.97 M
|
-$33.16 M
|
-$52.97 M
|
| EBITDA Ratio |
-2.28 |
-1.15 |
-0.6 |
-0.35 |
-0.4 |
-0.39 |
-0.19 |
-0.05 |
-0.33 |
-1.88 |
| Operating Income Ratio
|
-2.59
|
-1.19
|
-0.61
|
-0.38
|
-0.57
|
-0.49
|
-0.35
|
-0.44
|
-0.51
|
-2.83
|
| Total Other
Income/Expenses Net |
$634,000.00
|
-$26.61 M
|
-$40.18 M
|
-$113.41 M
|
-$46.64 M
|
-$28.86 M
|
-$26.38 M
|
-$16.99 M
|
$146.08 M
|
-$21.43 M
|
| Income Before Tax |
-$376.11 M |
-$278.17 M |
-$179.68 M |
-$188.79 M |
-$146.45 M |
-$101.87 M |
-$58.36 M |
-$57.58 M |
$105.47 M |
-$113.40 M |
| Income Before Tax Ratio
|
-2.59
|
-1.31
|
-0.79
|
-0.95
|
-0.84
|
-0.62
|
-0.38
|
-0.43
|
1.06
|
-4.02
|
| Income Tax Expense |
$223,000.00 |
$313,000.00 |
$409,000.00 |
-$19.36 M |
-$21,000.00 |
$811,000.00 |
$1.37 M |
-$9.68 M |
-$11.77 M |
-$2.46 M |
| Net Income |
-$111.40 M |
-$278.48 M |
-$180.09 M |
-$169.43 M |
-$146.43 M |
-$102.68 M |
-$59.73 M |
-$47.90 M |
$117.24 M |
-$110.94 M |
| Net Income Ratio |
-0.77 |
-1.31 |
-0.79 |
-0.85 |
-0.84 |
-0.63 |
-0.39 |
-0.36 |
1.17 |
-3.93 |
| EPS |
-1.5 |
-4.37 |
-3.01 |
-3.56 |
-3.46 |
-2.54 |
-1.54 |
-1.29 |
3.49 |
-4.43 |
| EPS Diluted |
-1.5 |
-4.37 |
-3.01 |
-3.56 |
-3.46 |
-2.54 |
-1.54 |
-1.25 |
3.17 |
-4.43 |
| Weighted Average Shares
Out |
$74.27 M
|
$63.76 M
|
$59.83 M
|
$47.54 M
|
$42.34 M
|
$40.42 M
|
$38.77 M
|
$37.00 M
|
$33.56 M
|
$25.04 M
|
| Weighted Average Shares
Out Diluted |
$74.27 M
|
$63.76 M
|
$59.83 M
|
$47.54 M
|
$42.34 M
|
$40.43 M
|
$38.77 M
|
$38.29 M
|
$37.58 M
|
$25.06 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
